SciELO - Scientific Electronic Library Online

 
vol.90 issue4Cardiovascular Involvement in Patients Recovered from COVID-19: Reality or Fantasy?Epicardial Adipose Tissue as Predictor of Coronary Artery Disease. A New Parameter to Stratify Cardiovascular Risk? author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista argentina de cardiología

On-line version ISSN 1850-3748

Abstract

SIGAL, ALAN R. et al. Present Use of Aspirin as an Antithrombotic Agent: Current or Outdated Drug?. Rev. argent. cardiol. [online]. 2022, vol.90, n.4, pp.294-303.  Epub Aug 01, 2022. ISSN 1850-3748.  http://dx.doi.org/10.7775/rac.es.v90.i4.20533.

Acetylsalicylic acid, or aspirin, is one of pharmacological tools most widely used in the care of cardiovascular patients. For years, it has been widely used in primary and secondary prevention to reduce cardiovascular risk.

Aspirin utilization has been questioned in recent times, with new trials in different scenarios of cardiovascular disease, such as peripheral vascular disease, stroke, primary prevention in the context of modern medical treatment, or in patients with acute coronary syndrome and concomitant need for anticoagulation. In turn, new studies question the need to maintain aspirin for 12 months together with a thienopyridine after an acute coronary syndrome, suggesting shorter regimens.

In this review, we evaluate the evidence behind the current indications for aspirin use in different clinical scenarios and provide recommendations on a case-by-case basis.

Keywords : Aspirin; Prevention; Evidence.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )